louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT01015573: Database Creation and Evaluation of Motor Function of Finger Tapping Measured by Magnetic Sensor System in Healthy Subjects
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Healthy
Lead sponsor: Hiroshima University
Sponsor class: OTHER
First posted: 2009-11-18
Enrollment: 375
Sex: ALL
Minimum age (years): 40
Maximum age (years): 79
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: The purpose of this study is to create a database of quantified finger movements. Using the evaluation system with magnetic sensors, the movements of finger tapping are measured and assessed by various indices, such as finger tapping interval, maximum amplitude of finger taps, and so on. In this study, the investigators will accumulate the data from healthy subjects for the purpose of applying this evaluation system to diagnosis support of nervous diseases in the future.


Eligibility criteria: Inclusion Criteria:

* Healthy
* Informed consent signed

Exclusion Criteria:

* Renal or hepatic dysfunction
* Severe heart disease
* Under medications for diabetes or hypertension
* Medical history of nervous disease, mental disease, muscular disease, cervical spondylosis, and/or apoplexy
* Feeling difficulty in daily movements
* Taking medicines which possibly affect the motor function of finger tapping.
* Implantation of pacemaker or DBS

Primary outcomes:
measure: movements of finger tapping
timeFrame: 1 day for measurement
Secondary outcomes:
Other outcomes:
Locations:
city: Hiroshima
country: Japan
facility: Hiroshima University
Study officials:
References:
Clinical trial NCT00138073: Effectiveness of a Computer Application in Improving Pulmonary Artery Catheter Waveform Interpretation
Official title: Effectiveness of a Web-Based Computer Application in Improving Pulmonary Artery Catheter Waveform Interpretation Among Nurses and Physicians
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: NA
Conditions: Pulmonary Artery Catheter Waveform Interpretation
Keywords: pulmonary artery catheter
waveform interpretation
computer-based learning
medical education
Lead sponsor: Massachusetts General Hospital
Sponsor class: OTHER
First posted: 2005-08-30
Enrollment: 55
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP

Brief summary: Skill with pulmonary artery catheter (PAC) waveform interpretation is inadequate among physicians and nurses. We, the investigators at Massachusetts General Hospital, have developed a web-based computer program to assist physicians and nurses in PAC waveform interpretation. We will study the effectiveness of this program on improving the interpretation of waveforms on a computer-based test.

Detailed description: The pulmonary artery catheter (PAC) guides diagnosis and treatment in the intensive care unit (ICU), but studies have shown that physicians and nurses collectively have inadequate skill in interpreting PAC waveforms. We have developed a Web-based application that provides physicians and nurses with rapid access to relevant PAC-related content for use in patient care situations. The application begins with a visual index that assists clinicians in the recognition of both normal and abnormal waveforms and provides waveform-specific links to concise advice on making accurate pressure measurements, troubleshooting system problems, and avoiding complications of catheter use. Initial evaluation will consist of a before-and-after trial to determine whether the application improves test performance in the areas of waveform recognition, accuracy of measurement, and appropriateness of action. Once the resource is in production, we will electronically log usage and survey users to evaluate the extent and effect of actual utilization.

Eligibility criteria: Inclusion Criteria:

* Critical care nurses
* House officers rotating through the medical Intensive Care Unit
* Fellows rotating through the medical Intensive Care Unit

Primary outcomes:
measure: Score on a Computer-based Test on Pulmonary Artery Catheter Waveform Interpretation
timeFrame: 1 month
Secondary outcomes:
measure: Individual and Collective Frequency of Use and Usage Patterns of the Web-based Waveform Interpretation Guide
timeFrame: 1 year
Other outcomes:
Locations:
city: Boston
country: United States
facility: Massachusetts General Hospital
state: Massachusetts
Study officials:
affiliation: Massachusetts General Hospital/Laboratory of Computer Science
name: Octo Barnett, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00564473: Use of Herbal Medicine in Internal Medicine Wards
Official title: Use of Herbal Medicine Among Patients Hospitalized in a Department of Internal Medicine: A Cross-Sectional Survey
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Herb-drug Interactions
Keywords: internal medicine
herbal medicine
prevalence
attitudes
herb-drug interaction
Lead sponsor: Shaare Zedek Medical Center
Sponsor class: OTHER
First posted: 2007-11-28
Enrollment: 200
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: patients hospitalized in a department of internal medicine

Brief summary: Herbs are physiologically active substances which can significantly affect the outcome of medical treatment, either by inhibiting or promoting drug disposition or through additive and synergistic effects when used in conjunction with conventional medications. Herb-drug interactions are potentially dangerous, and may be difficult to predict since regulation of the preparations is often lacking, and patients most often do not report the use of these products to their physicians. The risk for toxic effects and adverse interactions increases among high-risk groups, such as the elderly or patients with renal or hepatic disease. The purpose of this study is to study the prevalence of use of herbal medicine among patients hospitalized in the internal medicine department of an Israeli hospital, as well as examine the effect of herbal remedies on patient health, either beneficial or harmful. For this purpose, a questionnaire evaluating demographic data, medical history (both current and past), use of and attitudes towards herbal medicine will be administered to patients in the Department of Internal Medicine at the Shaare Zedek Medical Center in Israel. The Beck Depression Questionnaire will be used as well.


Eligibility criteria: Inclusion Criteria:

* Patients of either gender
* Age 18 years and older

Exclusion Criteria:

* Neurological deficit or other medical condition precluding responding to the questionnaires.

Primary outcomes:
measure: * prevalence of use of herbal medicine among patients hospitalized in the Department of Internal Medicine at the Shaare Zedek Medical Center in Jerusalem, Israel.
timeFrame: one year
Secondary outcomes:
measure: *prevalence of herb-drug interactions affecting treatment *rates of reporting use of herbal remedies *prevalence of toxic effects of herbal remedies *attitudes toward herbal medicine
timeFrame: one year
Other outcomes:
Locations:
city: Jerusalem
country: Israel
facility: Shaare Zedek Medical Center
city: Jerusalem
country: Israel
facility: Shaare Zedek Medical Center
Study officials:
affiliation: Shaare Zedek Medical Center
name: Noah Samuels, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Shaare Zedek Medical Center
name: Shoshanna Zevin, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01279473: Study to Evaluate Nilotinib in Adult Patients With Imatinib-resistant or Imatinib-intolerant Chronic Myelogenous Leukemia (CML), or Relapse/Refractory Ph+ Acute Lymphoblastic Leukemia (ALL) (Extension Study)
Official title: A Phase I/II Multicenter, Dose-escalation Study of Oral Nilotinib on a Continuous Daily Dosing Schedule in Adult Patients With Imatinib-resistant or Imatinib-intolerant Chronic Myelogenous Leukemia (CML), or Relapse/Refractory Ph+ALL (Philadelphia Positive Acute Lymphocytic Leukemia)(Extension Study)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
PHASE2
Conditions: Chronic Myelogenous Leukemia
Acute Lymphoblastic Leukemia
Keywords: Chronic Myelogenous Leukemia
CML
Acute Lymphoblastic Leukemia
Philadelphia Chromosome Positive, ph+ ALL
Acute Lymphoblastic Leukemia (Philadelphia Chromosome Positive)
Lead sponsor: Novartis
Sponsor class: INDUSTRY
First posted: 2011-01-19
Enrollment: 42
Sex: ALL
Minimum age (years): 20
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This study will investigate if nilotinib provides an improved safety and efficacy profile over that seen in patients receiving Imatinib.


Eligibility criteria: Inclusion Criteria:

* Patients who complete CAMN107A1101 and obtained Informed concent by document

Exclusion Criteria:

* None

Primary outcomes:
measure: Number of Adverse Events
timeFrame: 3 weeks
Secondary outcomes:
measure: Best hematologic response rate and Best cytogenetic response rate.
timeFrame: 3 years
measure: Percentage of BCR-ABL genes transcript and mutation status of BCR-ABL
timeFrame: 3 years
Other outcomes:
Locations:
city: Aichi
country: Japan
facility: Novartis Investigative Site
Study officials:
affiliation: Novartis Pharmaceuticals
name: Novartis Pharmaceuticals
role: STUDY_DIRECTOR
References:
Clinical trial NCT03212573: Impact of Implementation of an Enhanced Recovery After Surgery Program in Laparoscopic Roux-en-Y Gastric Bypass
Official title: Impact of Implementation of an Enhanced Recovery After Surgery Program in Laparoscopic Roux-en-Y Gastric Bypass
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE3
Conditions: Postoperative Pain
Lead sponsor: Hospital General Universitario Elche
Sponsor class: OTHER
First posted: 2017-07-11
Enrollment: 180
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: A prospective randomized study of patients undergoing Roux-en-Y gastric bypass will be randomized in 2 groups: those following an ERAS program and those ones following a standard protocol.

Postoperative pain 24 hours after surgery and hospital stay will be assessed.

Detailed description: A prospective randomized study of patients undergoing Roux-en-Y gastric bypass will be randomized in 2 groups: those following an Enhanced Recovery After Surgery (ERAS) program and those ones following a standard protocol. The ERAS program implies early liquids oral intake, early deambulation and multimodal analgesia (port sites infiltration with Bupivacain 0.5% associated with intravenous analgesia).

Postoperative pain 24 hours after surgery, as measured by Visual Analogic Scale, and hospital stay will be assessed.

Eligibility criteria: Inclusion Criteria:

* Body Mass Index (BMI) \>40 Kg/m2
* BMI \>35 Kg/m2 with obesity-associated comorbidities

Exclusion Criteria:

* Patients undergoing other bariatric procedures
* Patients undergoing bariatric revisional surgery

Primary outcomes:
measure: Postoperative pain
timeFrame: 24 hours after surgery
Secondary outcomes:
measure: Hospital stay
timeFrame: Days until patients´discharge: 2 days or more than 2 days
Other outcomes:
Locations:
city: Elche
country: Spain
facility: General Hospital Elche
state: Alicante
Study officials:
affiliation: Hospital Rey Juan carlos
name: Manuel Duran
role: STUDY_CHAIR
References:
Clinical trial NCT04439773: Intravenous Infusion of Lidocaine in Gastroscopy
Official title: Efficacy of Intravenous Infusion of Lidocaine in Sedation for ERCP: a Randomised Placebo-controlled Study
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE4
Conditions: Sedation
Keywords: intravenous lidocaine gastroscopy bucking
Lead sponsor: Shandong University
Sponsor class: OTHER
First posted: 2020-06-19
Enrollment: 130
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Participants are randomly assigned to controll group or lidocaine group. Participants of control group are given placebo while participants of lidocaine group are given lidocaine.
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: Intravenous infusion of lidocaine significantly reduces incidence of bucking when perfomed gastroscopy.

Detailed description: This study divide patients into two groups, the patients in lidocaine group will be given lidocaine; the control group will be given placebo .the primary endopiont was to investigate whether intravenous lidocaine can reduce incidence of bucking and movement in sedation of gastroscopy.

Eligibility criteria: Inclusion Criteria:

patients aged \>18 years who were scheduled for ERCP at Qilu hospital.

Exclusion Criteria:

patients with ASA (American Society of Anesthesiologists) Class 4 or 5, pre-existing hypoxemia (SpO2 \<90%), hypotension (systolic blood pressure \<90 mm Hg), bradycardia (HR\<50 beats/min), uncontrolled hypertension (SBP \>170 mm Hg, diastolic blood pressure\>100 mm Hg), severe renal or liver failure, pregnancy or lactation, allergy to lidocaine, atrioventricular block, epilepsy, and inability to give informed consen

Primary outcomes:
measure: the incidence of bucking during the procedure
timeFrame: half a year
Secondary outcomes:
measure: propofol consumption difference between the two groups
timeFrame: half a year
measure: the incidence of infusion pain when adminstrated propofol
timeFrame: half a year
measure: Safety assessed by the rate of hypoxia during the procedure
timeFrame: half a year
measure: Safety assessed by the rate of hypotention during the procedure
timeFrame: half a year
measure: Safety assessed by the rate of breadycardia during the procedure
timeFrame: half a year
measure: Safety assessed by the rate of required airway management during the procedure
timeFrame: half a year
measure: endoscopists satisfaction assessed by the performer
timeFrame: half a year
measure: patient satisfaction assessed by the patient
timeFrame: half a year
measure: anesthetist satisfaction
timeFrame: half a year
measure: pain socre after the gastroscopy
timeFrame: half a year
measure: fatigue score after the ERCP
timeFrame: half a year
Other outcomes:
Locations:
city: Jinan
country: China
facility: Department of Gastroenterology, Qilu Hospital, Shandong University
state: Shandong
Study officials:
affiliation: Qilu Hospital of Shandong University
name: Shan dong China
role: STUDY_CHAIR
References:
Clinical trial NCT00141973: Time Course of Procalcitonin and C Reactive Protein in Septic Patients Under Treatment With Corticosteroids
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Sepsis
Keywords: Procalcitonin
Sepsis
Corticosteroids
Lead sponsor: Ospedale Regionale Bellinzona e Valli
Sponsor class: OTHER
Collaborators: name: Brahms SA, D-16761 Hennigsdorf bei Berlin
First posted: 2005-09-02
Sex: ALL
Minimum age (years): 50
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Time perspective: PROSPECTIVE

Brief summary: A systemic treatment with corticosteroids has been advocated for various bacterial infectious diseases. Since the production of CRP is down-regulated by corticosteroids, a smaller increase or a more rapid decrease of this acute phase protein will:

1. suggest attenuated systemic inflammation, but
2. does not necessarily reflect adequate therapy of the infection.

For several reasons (good diagnostic tool for sepsis, induction not decreased by immunosuppressive therapy), procalcitonin could be a better marker for activity of sepsis in patients under corticosteroids. As this issue has not yet been examined the investigators will prospectively study the time-course of PTC and CRP in a well-defined septic patient group, that in adjunction to antibiotic therapy also received systemic corticosteroid treatment and compare it to a similar group without corticosteroid treatment.


Eligibility criteria: Inclusion Criteria:

* Acute exacerbation of chronic obstructive pulmonary disease (COPD) due to bacterial pneumonia

Exclusion Criteria:

* Chronic systemic use of corticosteroids

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Bellinzona
country: Switzerland
facility: Ospedale Regionale Bellinzona e Valli
state: Ticino
Study officials:
affiliation: Ospedale Regionale Bellinzona e Valli, CH-6500 Bellinzona
name: Andreas Perren, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06030973: Opinions of Healthcare Providers About a European Neuromodulation Register
Official title: Opinions of Healthcare Providers About a European Neuromodulation Register: an Online Survey
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Registry
Neuromodulation
Survey
Lead sponsor: Universitair Ziekenhuis Brussel
Sponsor class: OTHER
Collaborators: name: Vrije Universiteit Brussel
First posted: 2023-09-11
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_ONLY
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: In this study male and female adults who are involved in the management of chronic pain and more specifically in neuromodulation for pain (including but not limited to anesthesiologists, neurosurgeons, nurses) will be eligible to complete the survey. The survey will be spread at the 3ʳᵈ Joint Congress of the INS European Chapters (e-INS 2023) in Hamburg from 31/8/2023 to 2/9/2023.

Brief summary: The goal of this online survey is to gain further insights in the needs and burden for a European registry for neuromodulation, according to healthcare providers.


Eligibility criteria: Inclusion Criteria:

* Male and female adults who are involved in the management of chronic pain and more specifically in neuromodulation for pain (including but not limited to anesthesiologists, neurosurgeons, nurses).

Exclusion Criteria:

* Not involved in management of chronic pain through neuromodulation.

Primary outcomes:
measure: Healthcare providers their current degree of participation in a registry for neuromodulation.
timeFrame: Cross-sectional evaluation during 3th Joint Congress of the INS European Chapters (e-INS 2023) in Hamburg in August-September 2023.
measure: Healthcare providers their need for a European registry.
timeFrame: Cross-sectional evaluation during 3th Joint Congress of the INS European Chapters (e-INS 2023) in Hamburg in August-September 2023.
measure: Items that should be included in a registry for neuromodulation, according to healthcare providers.
timeFrame: Cross-sectional evaluation during 3th Joint Congress of the INS European Chapters (e-INS 2023) in Hamburg in August-September 2023.
measure: Access regulations to European registry for neuromodulation, according to healthcare providers.
timeFrame: Cross-sectional evaluation during 3th Joint Congress of the INS European Chapters (e-INS 2023) in Hamburg in August-September 2023.
Secondary outcomes:
Other outcomes:
Locations:
city: Hamburg
country: Germany
facility: Congres Center
Study officials:
References:
Clinical trial NCT00966173: International Melanoma Algorithm Training Study - IMATS
Official title: An International, Multicenter, Prospective, Non-controlled, Non-randomised, Clinical Study to Collect Impedance Data of Potentially Malignant Pigmented Nevi and Histological Diagnoses
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Malignant Melanoma
Lead sponsor: SciBase AB
Sponsor class: OTHER
First posted: 2009-08-26
Enrollment: 1800
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: This is an international, multicenter, prospective, non controlled, non randomized, clinical study to collect electrical impedance data of potentially malignant pigmented nevi and histological diagnoses (International Melanoma Algorithm Training Study \[IMATS\]). The study objective is to collect data for training and optimization of an algorithm that can classify skin lesions using electrical impedance, i.e., to identify malignant melanomas.


Eligibility criteria: Inclusion Criteria:

* Men and women of any ethnic group
* Lesion located on normal healthy skin
* Maximum number of eight lesions per patient
* etc.

Exclusion Criteria:

* Lesion under finger and toe nails
* Lesion located on eczema, psoriasis areas or similar
* Lesion located on scars
* etc.

Primary outcomes:
measure: Outcome measure not applicable. This is an algorithm training study.
timeFrame: Q1 2010
Secondary outcomes:
Other outcomes:
Locations:
city: Gothenburg
country: Sweden
facility: Sahlgrenska University Hospital, Dpt. of Dermatology
Study officials:
References:
Clinical trial NCT00950573: Arterial Calcifications in Nocturnal Hemodialysis and Renal Transplantation Versus Conventional Dialysis
Official title: Is Progression of Arteriosclerosis in ESRD Patients Inhibited by Nocturnal Hemodialysis or Renal Transplantation?
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Kidney Disease
Keywords: cardiovascular disease
endstage renal disease
Lead sponsor: Dianet Dialysis Centers
Sponsor class: OTHER
First posted: 2009-08-03
Enrollment: 184
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with ESRD

Brief summary: Objective:

1. To assess whether nocturnal hemodialysis and renal transplantation are associated with less progression of coronary arterial calcification, compared with conventional hemodialysis and peritoneal dialysis;
2. To identify the risk factors for coronary arterial calcification in dialysis and transplant patients, and to assess a possible interaction with treatment modality.

Detailed description: To assess whether nocturnal hemodialysis and renal transplantation are associated with less progression of coronary arterial calcification, compared with conventional hemodialysis and peritoneal dialysis; To identify the risk factors for coronary arterial calcification in dialysis and transplant patients, and to assess a possible interaction with treatment modality.

Eligibility criteria: Inclusion Criteria:

* ESRD
* current age \> 18 and \< 75 yr
* ability to understand the study procedures
* willingness to provide written informed consent

Exclusion Criteria:

* life expectancy \< 3 months
* claustrophobia
* allergy to iodinated contrast
* treatment incompliance, i.e. non-adherence to dialysis regimens and drug use
* GFR \< 30 ml/min (according to MDRD formula) in renal transplant patients
* pregnancy

Primary outcomes:
measure: Change in coronary artery calcification score
timeFrame: 3 yrs
Secondary outcomes:
Other outcomes:
Locations:
city: Utrecht
country: Netherlands
facility: Dianet Dialysis Centers
city: Utrecht
country: Netherlands
facility: University Medical Center Utrecht
Study officials:
affiliation: Amsterdam UMC, location VUmc
name: Brigit van Jaarsveld, MD, PHD
role: PRINCIPAL_INVESTIGATOR
References: